At-Home Ketamine: The Safety Questions Worth Asking

At-home ketamine went from a niche offering to a national industry in a very short time. Some of the programmes running it are careful. Others amount to a questionnaire, a prescription and a shipping label, and the distance between the two is entirely in the screening and the monitoring.

The appeal is obvious and not illegitimate. Clinic infusions are expensive, rarely covered by insurance, and require several hours and a driver each time. For someone in a rural county, or someone whose depression makes leaving the house difficult, an at-home programme removes real barriers. The question is not whether at-home ketamine should exist. It is what has to be in place for it to be practised responsibly.

Why regulators started paying attention

During the COVID-19 public health emergency, the DEA relaxed the requirement under the Ryan Haight Act for an in-person examination before a controlled substance could be prescribed remotely. That flexibility is what made at-home ketamine viable at scale, and the industry that grew around it grew fast.

Two things followed. The FDA issued a public communication about the risks of compounded ketamine used without monitoring, flagging sedation, dissociation, blood pressure effects and the possibility of misuse when a psychoactive controlled substance is taken unsupervised. And the DEA proposed, withdrew, revised and repeatedly extended the telemedicine controlled-substance rules while it worked towards a permanent framework.

The practical consequence is that this is a live regulatory area, and a clinic operating today may be operating under a temporary extension. That is not improper in itself, but any confident statement you read about the permanent rules — including on this page — should be checked against the DEA's current guidance.

What adequate screening actually covers

This is what separates the two kinds of programme, and it is assessable from the outside. Proper screening involves a conversation with a clinician, not only a form, and covers at minimum the following ground.

Psychiatric history

Not just "do you have depression." A clinician needs the shape of the illness: how long, how many episodes, what treatments at what doses for how long, what happened with each. Two things in particular are being looked for. Psychosis or a psychotic disorder, personal and often family history, because ketamine's dissociative and perceptual effects are a poor fit with an underlying psychotic illness. And bipolar disorder, including hypomanic episodes the person may never have thought of as symptoms.

They should also establish whether standard treatments have genuinely been tried adequately, because if they haven't, that is usually the better next step. What "treatment-resistant" actually means is worth reading first, because the term is applied far more loosely in marketing than in medicine.

Cardiovascular history and a blood pressure reading

Ketamine raises blood pressure and heart rate. Uncontrolled hypertension, a history of aneurysm or arteriovenous malformation, recent cardiac events and significant arrhythmia all weigh heavily against treatment. A programme intending to dose you at home should want a recent blood pressure reading and should tell you how to take one. If nobody has asked about your heart, nobody has screened you.

Substance use, asked directly

Ketamine has genuine misuse potential. A history of ketamine misuse specifically, and a broader history of substance use disorder, are both relevant. So is current alcohol use, which people habitually under-report.

Pregnancy, medications and other conditions

Pregnancy and pregnancy planning. A full medication list including over-the-counter products and supplements. Liver disease. Anything affecting airway or breathing. And a practical question about your living situation: who else is in the house, whether there are children, whether the medication can be stored securely.

What monitoring should look like

In a clinic, monitoring is a person in the room with a blood pressure cuff. At home it has to be reconstructed from other parts, and a responsible programme builds it deliberately.

A support person. Physically present, awake, aware of what is happening, for the session and the period afterwards. Not in another building. Not asleep upstairs. They need to know what you have taken, roughly what to expect, that you may be disoriented and unsteady, that you should not drive or make decisions that day, and when to call for help. Programmes treating this as a suggestion have removed the last safety layer they had.

Blood pressure readings, before dosing at minimum. A programme that supplies or requires a cuff is taking the cardiovascular risk seriously.

Structured check-ins with the prescriber after early sessions, covering how you responded, side effects, mood, and whether to continue. Not a satisfaction survey. Not a chatbot.

Dose control and quantity limits. Small quantities at a time, with refills contingent on the check-ins actually happening.

A route to a human out of hours. You should know, before your first session, who to call at nine at night.

An escalation plan for what happens if your mood worsens, with explicit instruction that in a crisis you call or text 988 or go to an emergency room. An at-home programme is not an emergency service, and telehealth is not appropriate for a psychiatric emergency.

Red flags in a provider

These are the ones worth walking away from, in rough order of how much they tell you.

• The fee depends on the outcome. "Pay only if approved," "free if you don't qualify," or a package price that only exists once you are accepted. The person making the clinical decision now has a financial interest in one answer. Nothing else here matters as much.
• No medical history is taken. A questionnaire asking how sad you feel and nothing about your heart, your psychiatric history or your medications is not a history.
• No conversation with a clinician at all. Prescription issued on a form review, with no video or telephone consultation.
• No screening for psychosis or substance use — the two exclusions most specific to this drug. Their absence is diagnostic of the operation.
• No named clinician. If you cannot find out who is prescribing and where they are licensed, you cannot check either. You are entitled to know — see your rights as a telehealth patient.
• No requirement for a support person, or a vague suggestion that it might be nice to have someone around.
• No follow-up, or follow-up that is purely automated.
• Claims of guaranteed results. Nobody can promise you a response, and language about cures or life-changing outcomes is not clinical language.
• Off-label described as FDA-approved. At-home ketamine is off-label. A site implying otherwise by borrowing Spravato's approval is doing that deliberately — the two are set out side by side here.
• Pressure at the point of decision. Countdown timers, expiring discounts, a package upsell mid-consultation.

These overlap heavily with how to spot a prescription mill, because it is the same business model applied to a different drug.

Questions worth asking, verbatim

Who will be prescribing, and in which states are they licensed? Will I speak to them live before a decision? What would rule me out? Do you require a blood pressure reading, and a support person present? What check-ins are scheduled, and with whom? What do I do if something goes wrong at 2am? Is the fee charged whether or not I am accepted? Is what you are prescribing FDA-approved for depression?

A good provider answers all of those without hesitating, because the answers are just descriptions of how they work. Hesitation on the first three is informative.

Where this fits

At-home ketamine is not a first-line treatment and not a replacement for the rest of depression care. It is used alongside an antidepressant and, where possible, psychotherapy, in people whose depression has not responded to adequate trials. The full picture is in our guide to ketamine for treatment-resistant depression.

What our own screening covers is set out on the ketamine therapy page, and you can book a consultation to have the conversation. It is a consultation, not a decision made in advance, and some people are told no.